- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02579993
ABCB5 as a Prognostic Marker in Survival of Cultivated Limbal Stem Cell Transplantation
March 5, 2018 updated by: Instituto de Oftalmología Fundación Conde de Valenciana
ABCB5 as a Prognostic Marker in Survival of Cultivated Limbal Stem Cell Transplantation Expanded in Vitro on Amniotic Membrane in Patients With Limbal Stem Cell Deficiency.
In this study the prognostic value of ABCB5 in survival of the limbal stem cell transplantation expanded in vitro on amniotic membrane for corneal surface reconstruction in patients with limbal stem cell deficiency will be analyzed.
Study Overview
Status
Terminated
Conditions
Detailed Description
There are several diseases that cause the cornea to lose its clarity and directly affects the vision of the individual, therefore, the use of limbal stem cells has been having increasing acceptance in the field of medical therapy.
An open clinical study is running with patients with limbal stem cell deficiency, performing a limbal stem cell transplantation expanded in vitro on amniotic membrane and the value of ABCB5 as a prognostic factor in the survival of transplant will be determined.
The corneal surface status will be the primary endpoint.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mexico City, Mexico, 06800
- Instituto de Oftalmología Conde de Valenciana
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Bilateral limbal stem cell deficiency of any etiology.
- Corneal impression cytology positive for goblet cells.
- Ocular ultrasound results within normal parameters.
- Agree to participate in the study and sign the informed consent.
Exclusion Criteria:
1. Active immunological diseases.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Stem Cell Transplantation
Cultivated Limbal Stem Cell Transplantation
|
A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue.
The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective clinical evaluation
Time Frame: 6 months
|
A grading system from 0 to 4 using photographs taken with slit lamp, will be used to determine by two independent examiners the degree of corneal transparency and superficial vascularization.
|
6 months
|
|
Objective clinical evaluation
Time Frame: 12 months
|
A grading system from 0 to 4 using photographs taken with slit lamp, will be used to determine by two independent examiners the degree of corneal transparency and superficial vascularization.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Corneal cells morphology
Time Frame: 6 months
|
Evaluation of the presence of epithelial, conjunctival or mixed cells with in vivo confocal microscopy and impression cytology
|
6 months
|
|
Corneal cells morphology
Time Frame: 12 months
|
Evaluation of the presence of epithelial, conjunctival or mixed cells with in vivo confocal microscopy and impression cytology
|
12 months
|
|
Quality of life questionnaire
Time Frame: 6 months
|
Modified National Eye Institute Visual Function Questionnaire 25 questionnaire
|
6 months
|
|
Quality of life questionnaire
Time Frame: 12 months
|
Modified National Eye Institute Visual Function Questionnaire 25 questionnaire
|
12 months
|
|
Visual acuity
Time Frame: 6 months
|
Visual acuity in the Logarithm of the Minimum Angle of Resolution scale
|
6 months
|
|
Visual acuity
Time Frame: 12 months
|
Visual acuity in the Logarithm of the Minimum Angle of Resolution scale
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Yonathan Garfias, MD, PhD, Instituto de Oftalmología Conde de Valenciana
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (Actual)
March 1, 2018
Study Completion (Actual)
March 1, 2018
Study Registration Dates
First Submitted
October 11, 2015
First Submitted That Met QC Criteria
October 17, 2015
First Posted (Estimate)
October 20, 2015
Study Record Updates
Last Update Posted (Actual)
March 6, 2018
Last Update Submitted That Met QC Criteria
March 5, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CI-051-2014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Limbal Stem Cell Deficiency
-
BRIM Biotechnology Inc.University of PennsylvaniaAvailableLimbal Stem Cell Deficiency (LSCD)United States
-
The S.N. Fyodorov Eye Microsurgery State InstitutionRecruitingLimbal Stem-cell DeficiencyRussian Federation
-
University of California, Los AngelesNational Eye Institute (NEI); California Institute for Regenerative Medicine...Active, not recruiting
-
National Taiwan University HospitalRecruiting
-
Siriraj HospitalOsaka UniversityCompletedLimbal Stem-cell DeficiencyThailand
-
CellSeed France S.A.R.L.FGK Clinical Research GmbHWithdrawnLimbal Stem Cell DeficiencyGermany
-
National Taiwan University HospitalRecruiting
-
Klinikum Chemnitz gGmbHInstitute of Anatomy TU DresdenCompletedLimbal Stem-cell Deficiency
-
Royan InstituteSmall Business Developing Center; Labafi Nejad Eye Research CenterCompletedLimbal Stem Cell DeficiencyIran, Islamic Republic of
-
Royan InstituteCompletedLimbal Stem Cell Deficiency (LSCD)
Clinical Trials on Pannus and conjunctival dissection
-
Beijing Tongren HospitalCompleted
-
Medical University InnsbruckUnknown
-
Assiut UniversityUnknown
-
Walter Reed National Military Medical CenterState University of New York College of Optometry; Schepens Eye Research InstituteCompletedKeratoconjunctivitis SiccaUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingConjunctivitis | Eye DiseaseItaly
-
Shaaban ElwanMinia UniversityCompleted
-
Wellington HospitalBaxter Healthcare CorporationUnknown
-
Taihe HospitalNot yet recruiting
-
Maimonides Medical CenterCompletedRectal Cancer | Colon CancerUnited States
-
ORA, Inc.CompletedFood HypersensitivityUnited States